4 research outputs found
EVALUATION OF PRECONCEPTION PREPARATION IN PREVENTION OF COMPLICATED GESTATION IN WOMEN AFTER MYOMECTOMY
We examined 300 women with uterine fibroids and carried out over the next 12-24 months myomectomy, 150 of which had preconception care (treatment), 150 - not. The average age of women - 33,4 +/- 3,2 years, duration of disease (uterine fibroids) - 4,25 +/- 1,4 years. The comparative evaluation of the effectiveness of preconception care in the prevention of complications of pregnancy in women after myomectomy is presented
EVALUATION OF PRECONCEPTION PREPARATION IN PREVENTION OF COMPLICATED GESTATION IN WOMEN AFTER MYOMECTOMY
We examined 300 women with uterine fibroids and carried out over the next 12-24 months myomectomy, 150 of which had preconception care (treatment), 150 - not. The average age of women - 33,4 +/- 3,2 years, duration of disease (uterine fibroids) - 4,25 +/- 1,4 years. The comparative evaluation of the effectiveness of preconception care in the prevention of complications of pregnancy in women after myomectomy is presented
Effect of combined oral contraceptives conaining drospirenone + ethinylestradiol on the mammary gland condition in women of reproductive age
Drospirenone, as a part of combined oral contraceptives, has an antiproliferative effect on hyperplastic processes in the organs of the female reproductive system. Individual selection of COCs taking into account the dose and properties of the gestagenic and estrogenic components allows, with contraceptive and non-contraceptive purposes, to prescribe it to women of reproductive age. Intake of COC containing drospirenone + ethinyl estradiol is not associated with impaired drug tolerance due to complaints of soreness and breast engorgement in the first 3 months. 6 months of COCs containing drospirenone + ethinyl estradiol are significantly associated with a decrease in the frequency of clinical and US-signs of dyshormonal dysplasia of the breast. © 2018 Stavropol State Medical University. All rights reserved
Effect of combined oral contraceptives conaining drospirenone + ethinylestradiol on the mammary gland condition in women of reproductive age
Drospirenone, as a part of combined oral contraceptives, has an antiproliferative effect on hyperplastic processes in the organs of the female reproductive system. Individual selection of COCs taking into account the dose and properties of the gestagenic and estrogenic components allows, with contraceptive and non-contraceptive purposes, to prescribe it to women of reproductive age. Intake of COC containing drospirenone + ethinyl estradiol is not associated with impaired drug tolerance due to complaints of soreness and breast engorgement in the first 3 months. 6 months of COCs containing drospirenone + ethinyl estradiol are significantly associated with a decrease in the frequency of clinical and US-signs of dyshormonal dysplasia of the breast. © 2018 Stavropol State Medical University. All rights reserved